CD274 and cancer: Site‐specific glycoproteomic profiling of PD‐L1 in cancer cells will certainly shed light on the molecular role played by receptor site‐specific glycosylation in the differential binding to DL variants and support the design of novel glycoengineered DL variants capable of circumventing glycan‐mediated binding inhibition.